Join
Live feed
·
INSIDERFilingvia Quantisnow
Zymeworks Inc. logo

Chair & CEO Galbraith Kenneth converted options into 64,000 shares and sold $689,819 worth of shares (30,424 units at $22.67), increasing direct ownership by 17% to 226,842 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
ZYME· Zymeworks Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ZYME (Zymeworks Inc.) and more on Quantisnow.

Chair & CEO Galbraith Kenneth converted options into 64,000 shares and sold $689,819 worth of shares (30,424 units at $22.67), increasing direct ownership by 17% to 226,842 units (SEC Form 4) | Quantisnow